See more : Focus Lighting and Fixtures Limited (FOCUS.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Polarean Imaging plc (PLLWF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Polarean Imaging plc, a leading company in the Medical – Devices industry within the Healthcare sector.
- Smartpay Holdings Limited (SMP.AX) Income Statement Analysis – Financial Results
- Carbon Minerals Limited (CRM.AX) Income Statement Analysis – Financial Results
- SBM Offshore N.V. (SBMO.AS) Income Statement Analysis – Financial Results
- GetBusy plc (GETB.L) Income Statement Analysis – Financial Results
- Bastion Minerals Limited (BMO.AX) Income Statement Analysis – Financial Results
Polarean Imaging plc (PLLWF)
About Polarean Imaging plc
Polarean Imaging plc operates as a medical drug-device combination company serving the medical imaging market in the United States, Canada, Germany, and the United Kingdom. The company engages in the development and commercialization of gas polarizer devices and ancillary instruments. It develops equipment that enables existing magnetic resonance imaging (MRI) systems to achieve a level of pulmonary functional imaging and specializes in the use of hyperpolarized xenon gas (129Xe) as an imaging agent to visualize ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream, and in the pulmonary vasculature; and a novel diagnostic approach. The company is also involved in the development and manufacture of MRI radiofrequency coils, which are required components for imaging 129Xe in the MRI system. Polarean Imaging plc was incorporated in 2016 and is based in Durham, North Carolina.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 890.93K | 1.03M | 1.19M | 1.06M | 2.30M | 2.44M | 1.24M | 880.65K | 902.34K | 965.43K |
| Cost of Revenue | 555.45K | 684.73K | 677.40K | 346.30K | 925.61K | 633.46K | 297.22K | 488.89K | 308.56K | 168.03K |
| Gross Profit | 335.48K | 348.28K | 508.03K | 710.47K | 1.38M | 1.81M | 939.95K | 391.76K | 593.78K | 797.40K |
| Gross Profit Ratio | 37.66% | 33.71% | 42.86% | 67.23% | 59.78% | 74.03% | 75.98% | 44.49% | 65.80% | 82.60% |
| Research & Development | 4.19M | 607.76K | 638.59K | 480.89K | 161.31K | 642.46K | 176.11K | 145.44K | 162.98K | 269.83K |
| General & Administrative | 3.34M | 8.46M | 6.52M | 5.05M | 6.01M | 6.16M | 4.05M | 1.28M | 1.19M | 769.96K |
| Selling & Marketing | 3.56M | 3.31M | 5.56M | 917.78K | 324.79K | 31.77K | 28.75K | 35.24K | 25.39K | 86.41K |
| SG&A | 6.90M | 11.78M | 12.08M | 5.97M | 6.33M | 6.19M | 4.08M | 1.32M | 1.21M | 856.37K |
| Other Expenses | 1.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 12.89M | 14.02M | 14.82M | 7.33M | 7.39M | 7.07M | 4.86M | 1.45M | 1.51M | 869.11K |
| Cost & Expenses | 13.45M | 14.70M | 15.50M | 7.67M | 8.31M | 7.71M | 5.16M | 1.94M | 1.81M | 1.04M |
| Interest Income | 759.00 | 35.05K | 2.59K | 100.77K | 508.00 | 184.00 | 129.00 | 147.00 | 159.31K | 37.69K |
| Interest Expense | 15.99K | 23.76K | 20.74K | 19.73K | 91.68K | 188.06K | 34.06K | 4.32K | 0.00 | 0.00 |
| Depreciation & Amortization | 959.78K | 1.02M | 918.40K | 942.62K | 775.69K | 598.87K | 387.84K | 9.35K | 9.99K | 12.74K |
| EBITDA | -11.19M | -12.78M | -13.38M | -5.73M | -5.26M | -4.64M | -3.55M | -1.05M | -617.40K | -58.97K |
| EBITDA Ratio | -1,256.55% | -1,243.32% | -1,128.88% | -532.81% | -228.79% | -190.22% | -287.32% | -118.80% | -68.42% | -6.11% |
| Operating Income | -12.56M | -13.67M | -14.32M | -6.62M | -6.01M | -5.27M | -3.92M | -1.06M | -627.39K | -71.71K |
| Operating Income Ratio | -1,409.33% | -1,323.38% | -1,207.70% | -626.02% | -261.27% | -215.93% | -317.17% | -119.86% | -69.53% | -7.43% |
| Total Other Income/Expenses | 671.36K | -235.03K | 300.44K | 81.04K | -91.17K | -187.87K | -33.93K | -4.17K | -159.31K | -37.69K |
| Income Before Tax | -11.88M | -13.91M | -14.02M | -6.53M | -6.10M | -5.45M | -3.96M | -1.06M | -1.07M | -109.40K |
| Income Before Tax Ratio | -1,333.97% | -1,346.13% | -1,182.36% | -618.35% | -265.24% | -223.63% | -319.91% | -120.33% | -118.66% | -11.33% |
| Income Tax Expense | 0.00 | -211.26K | 1.00 | 100.77K | 508.00 | 465.85K | -18.62K | 0.00 | 0.00 | 0.00 |
| Net Income | -11.88M | -13.91M | -14.02M | -6.53M | -6.10M | -5.45M | -3.96M | -1.06M | -1.07M | -109.40K |
| Net Income Ratio | -1,333.97% | -1,346.13% | -1,182.36% | -618.35% | -265.24% | -223.63% | -319.91% | -120.33% | -118.66% | -11.33% |
| EPS | -0.06 | -0.07 | -0.07 | -0.04 | -0.06 | -0.08 | -0.14 | -0.99 | -1.49 | -0.17 |
| EPS Diluted | -0.06 | -0.07 | -0.07 | -0.04 | -0.06 | -0.08 | -0.14 | -0.99 | -1.49 | -0.17 |
| Weighted Avg Shares Out | 214.28M | 211.95M | 196.96M | 150.21M | 107.20M | 69.94M | 28.46M | 1.07M | 717.11K | 627.93K |
| Weighted Avg Shares Out (Dil) | 214.28M | 211.95M | 196.96M | 150.21M | 107.20M | 69.94M | 28.46M | 1.07M | 717.11K | 627.92K |
Polarean Imaging focused on gaining commercial traction for XENOVIEW
Polareran Imaging carries out first clinical scan in US
Polarean Imaging receives first XENOVIEW order
Polarean Imaging gains access to funds after new bridge bank is formed; share suspension lifted
Polarean Imaging looking to gain commercial traction for its XENOVIEW
Polarean Imaging hails as a 'major milestone' FDA designation for XENOVIEW
Source: https://incomestatements.info
Category: Stock Reports